Clinical Trial: Effect of Anti CD20 in Pemphigus Desease
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Traitment of Patients Presenting Pemphigus With Anti CD20 (Mabthera).
Brief Summary: to treat in an open non comparative clinical study patients presenting pemphigus with corticodependance, corticoresistance and contre-indication to systemic steroids.
Detailed Summary:
Sponsor: University Hospital, Rouen
Current Primary Outcome: primary end-point was the rate of CR three months after the last infusion of Rituximab
Original Primary Outcome:
Current Secondary Outcome:
- secondary end-points were :
- rate of CR during the study period
- time from the start of Rituximab to CR
- number and length of time to relapses
- treatment tolerance
Original Secondary Outcome:
Information By: University Hospital, Rouen
Dates:
Date Received: September 13, 2005
Date Started: June 2003
Date Completion:
Last Updated: June 17, 2013
Last Verified: June 2013